- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Mitomycin C, Normal saline
- Drug
- Lead sponsor
- Li, Zhiping, M.D.
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 162
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Primary Sclerosing Cholangitis (PSC)
- Interventions
- LB-P8 low-dose, LB-P8 high-dose, Placebo
- Drug
- Lead sponsor
- LISCure Biosciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 7
- States / cities
- Sacramento, California • Aurora, Colorado • Iowa City, Iowa + 4 more
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Childhood Myelodysplastic Syndromes, de Novo Myelodysplastic Syndromes, Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
- Interventions
- cytarabine, daunorubicin hydrochloride, etoposide, valspodar, filgrastim, busulfan, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, aldesleukin, clinical observation, pharmacological study
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 15 Years to 59 Years
- Enrollment
- 720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Autoimmune Hepatitis, Primary Sclerosing Cholangitis
- Interventions
- No interventions
- Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Not listed
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2033
- U.S. locations
- 8
- States / cities
- Palo Alto, California • Indianapolis, Indiana • St Louis, Missouri + 5 more
- Conditions
- Long COVID, Long COVID-19, Long COVID19
- Interventions
- BrainHQ/Active Comparator Activity, BrainHQ, PASC CoRE, tDCS-active, tDCS-sham
- Other · Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 20 more
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC)
- Interventions
- Cilofexor
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 4
- States / cities
- Miami, Florida • Orlando, Florida • Knoxville, Tennessee + 1 more
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Not listed
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Miami, Florida • Bethesda, Maryland + 2 more
- Conditions
- Long Covid-19, PASC Post Acute Sequelae of COVID 19, Brain Fog, Fatigue
- Interventions
- rTMS
- Device
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- NGM282, Placebo
- Biological · Other
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 26
- States / cities
- Sacramento, California • San Clemente, California • San Francisco, California + 21 more
- Conditions
- Primary Sclerosing Cholangitis (PSC)
- Interventions
- LUM001
- Drug
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- La Jolla, California • Sacramento, California • Aurora, Colorado + 2 more
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Sulfasalazine, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 15 Years to 80 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Chestnut Hill, Massachusetts
- Conditions
- Social Anxiety Disorder
- Interventions
- Fasedienol Nasal Spray, Placebo Nasal Spray
- Drug
- Lead sponsor
- VistaGen Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 21 more
- Conditions
- Post-acute Sequelae SARS-CoV-2 Infection (PASC)
- Interventions
- Active tDCS, Sham tDCS
- Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Vancomycin, Placebo
- Drug · Other
- Lead sponsor
- Elizabeth Carey
- Other
- Eligibility
- 18 Years to 76 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Jacksonville, Florida + 1 more
- Conditions
- Primary Sclerosing Cholangitis (PSC)
- Interventions
- Genetic Analysis
- Genetic
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 5 Years to 90 Years
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Cilofexor, Placebo to match cilofexor
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 16
- States / cities
- Sacramento, California • San Francisco, California • Aurora, Colorado + 10 more
- Conditions
- Post Acute COVID-19 Syndrome, Long COVID, Long Covid19, COVID-19 Recurrent, Post-Acute COVID-19, Post-Acute COVID-19 Infection, SARS-CoV2 Infection, Post Acute Sequelae of COVID-19, Dysautonomia, Dysautonomia Like Disorder, Dysautonomia Orthostatic Hypotension Syndrome, Post COVID-19 Condition, Post-COVID Syndrome, Post COVID-19 Condition, Unspecified, Post-COVID-19 Syndrome
- Interventions
- stellate ganglion block with 0.5% bupivacaine
- Drug
- Lead sponsor
- Jonathann Kuo, MD
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Cenicriviroc 150 mg
- Drug
- Lead sponsor
- Tobira Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 5
- States / cities
- La Jolla, California • Sacramento, California • San Francisco, California + 2 more
- Conditions
- Primary Sclerosing Cholangitis (PSC)
- Interventions
- SpyGlass DS I - II
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- Davis, California • Sacramento, California • Salt Lake City, Utah
- Conditions
- Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- pegylated liposomal doxorubicin hydrochloride, PSC 833
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- PSC
- Interventions
- Not listed
- Lead sponsor
- PSC Partners Seeking a Cure
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 11
- States / cities
- Sacramento, California • San Francisco, California • New Haven, Connecticut + 6 more
- Conditions
- COVID-19, Post Acute Sequelae of SARS-CoV-2
- Interventions
- Muse S™ Headband system
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- SARS-CoV-2 Infection, COVID-19, Coronavirus Infection, SARS (Severe Acute Respiratory Syndrome)
- Interventions
- Not listed
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID
- Interventions
- TNX-102 SL, Placebo SL Tablet
- Drug
- Lead sponsor
- Tonix Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Oceanside, California • Santa Ana, California + 25 more